Current Edition

Clinical Market in Russia

More than six years have passed since the federal law ‘On Circulation
of Medicines’ came into effect, replacing the law ‘On Medicines’.
The adoption of the new legislation has significantly impacted the
pharmaceutical market in Russia as a whole, and the clinical trials
sector in particular. The business had to be largely rebuilt according
to the new rules of the game. Today, looking back on the past few
years, Svetlana Zavidova, Executive Director of the Association of
Clinical Trials Organizations (ACTO) says that the regulatory system
has been completed now, and the clinical trials market in Russia has
moved into a stable phase.